# US 2014/0193902 A1 · Pdx1 expressing endoderm > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193902 A1 - Document ID: US20140193902A1 - Status: Published application - Kind: A1 - Application number: 14/107,970 - Filed: 2013-12-16 - Published: 2014-07-10 - Earliest claimed: 2004-04-27 - Assignees: ViaCyte, Inc. - Applicants: ViaCyte, Inc. - Inventors: Kevin Alan D'Amour; Alan D. Agulnick; Susan Eliazer; Emmanuel E. Baetge - Web page: https://patentgrep.com/patent/US20140193902A1 ## CPC - C12N 5/0608: {Germ cells (production of embryos, nuclear transfer A01K67/027)} - C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)} - C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies} - C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)} - C12N 5/0676: {Pancreatic cells} - C12N 5/0679: {Cells of the gastro-intestinal tract} - C12N 15/1086: {Preparation or screening of expression libraries, e.g. reporter assays} - C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes - A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) - C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components - C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2) - C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10 - C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor - C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance - C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] - C12N 2501/415: Wnt; Frizzeled - C12N 2502/02: embryonic cells - C12N 2502/13: connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts" - C12N 2503/00: Use of cells in diagnostics - C12N 2506/02: from embryonic cells - C12N 2510/00: Genetically modified cells - C12Q 2600/158: Expression markers - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed. ## Claims ### Claim at position 1 1-18. (canceled) ### Claim 19 An in vitro population of cells comprising PDX1-positive endoderm cells, wherein said population of cells is in contact with a retinoid. ### Claim 20 (depends on 19) The population of cells of claim 19, wherein the cell population expresses SOX17. ### Claim 21 (depends on 19) The population of cells of claim 19, wherein the PDX1-positive endoderm cells are PDX1-positive foregut endoderm cells. ### Claim 22 (depends on 21) The population of cells of claim 21, wherein the PDX1-positive foregut endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the anterior portion of the gut tube. ### Claim 23 (depends on 19) The population of cells of claim 19, wherein said population of cells is in contact with a TGFβ superfamily member. ### Claim 24 (depends on 21) The population of cells of claim 21, wherein the PDX1-positive foregut endoderm cells express the homeobox A13 (HOXA13) gene. ### Claim 25 (depends on 19) The population of cells of claim 19, wherein the retinoid is retinoic acid. ### Claim 26 (depends on 19) The population of cells of claim 19, wherein said population of cells is in contact with an FGF-family growth factor. ### Claim 27 An in vitro population of cells comprising PDX1-positive endoderm cells expressing a marker selected from the group consisting of HOXA13, PROX1 and HOXC6. ### Claim 28 (depends on 27) The in vitro population of cells of claim 27, wherein the PDX1-positive endoderm cells are derived from a human pluripotent stem cell. ### Claim 29 (depends on 27) The in vitro population of cells of claim 27, wherein said cells are in contact with a retinoid. ### Claim 30 (depends on 27) The in vitro population of cells of claim 27, wherein said cells are in contact with an FGF-family growth factor. ### Claim 31 (depends on 27) The in vitro population of cells of claim 27, wherein the PDX1-positive endoderm cells are multipotent cells that can differentiate into cells, tissues or organs derived from the anterior portion of the gut tube. ### Claim 32 (depends on 27) The in vitro population of cells of claim 27, wherein the cell culture expresses SOX17. ### Claim 33 An in vitro population of PDX1-positive endoderm cells obtained by differentiation of pluripotent cells, wherein the population of PDX1-positive endoderm cells expresses HOXA13, PROX1 or HOXC6. ### Claim 34 (depends on 33) The cell population of claim 33, wherein the PDX1-positive endoderm cells are derived from a human embryonic stem cell. ### Claim 35 (depends on 33) The cell population of claim 33, wherein said cell population is in contact with a retinoid. ### Claim 36 (depends on 33) The cell population of claim 33, wherein said cell population is in contact with an FGF-family growth factor. ### Claim 37 (depends on 33) The cell population of claim 33, wherein the population of PDX1-positive endoderm cells are multipotent cells that can differentiate into cells of the gut tube. ### Claim 38 (depends on 33) The cell population of claim 33, wherein the population of PDX1-positive endoderm cells expresses SOX17.